Correction: Li et al. Zanubrutinib Ameliorates Cardiac Fibrosis and Inflammation Induced by Chronic Sympathetic Activation. Molecules 2023, 28, 6035

Li, Wenqi; Zhu, Shuwen; Liu, Jing; Liu, Zhigang; Zhou, Honggang; Zhang, Qianyi; Yang, Yue; Chen, Li; Guo, Xiaowei; Zhang, Tiantian; Meng, Lingxin; Chai, Dan; Tang, Guodong; Li, Xiaohe; Yang, Cheng

doi:10.3390/molecules31101561

In the original publication [1], there was a mistake in Figure 1. The authors noticed an error in Figure 1b when they reviewed this published work. The incorrect image was used for the ISO + Met group. The corrected Figure 1 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Figure 1. ZB prevents ISO-induced cardiac dysfunction. (a) Dosing regimen in ISO-induced cardiac fibrosis model. Mice were treated by daily subcutaneous injection of 10 mg kg⁻¹ d⁻¹ ISO for 7 days. For 7 days, 10 mg/kg, 20 mg/kg ZB, 30 mg/kg Met or equal volumes of Saline was gavaged daily as indicated. Met was used as a positive control; (b) Representative echocardiographic M-mode images of left ventricles from mice at day 8; (c) Echocardiographic measurement of LVEF (n = 6); (d) Echocardiographic measurement of LVFS (n = 6); (e) Quantitative analysis of LVPW;d (n = 6); (f) The mRNA levels of ANP in heart tissues (n = 6); (g) The mRNA levels of BNP in heart tissues (n = 6); Quantification of ANP and BNP were normalized to GAPDH. The data are shown as mean ± SEM (one-way ANOVA with Tukey’s post-hoc multiple comparison tests). ***, p < 0.001, ****, p < 0.0001 vs. Saline; #, p < 0.05, ##, p < 0.01, ###, p < 0.001, ####, p < 0.0001 vs. ISO. ISO, isoproterenol; Met, metoprolol; ZB, Zanubrutinib; LVEF, left ventricular ejection fraction; LVFS, left ventricular fractional shortening; LVPW;d, diastolic left ventricular posterior wall thickness.

Reference

Li, W.; Zhu, S.; Liu, J.; Liu, Z.; Zhou, H.; Zhang, Q.; Yang, Y.; Chen, L.; Guo, X.; Zhang, T.; et al. Zanubrutinib Ameliorates Cardiac Fibrosis and Inflammation Induced by Chronic Sympathetic Activation. Molecules 2023, 28, 6035. [Google Scholar] [CrossRef] [Scilit] [PubMed]

Figure 1. ZB prevents ISO-induced cardiac dysfunction. (a) Dosing regimen in ISO-induced cardiac fibrosis model. Mice were treated by daily subcutaneous injection of 10 mg kg⁻¹ d⁻¹ ISO for 7 days. For 7 days, 10 mg/kg, 20 mg/kg ZB, 30 mg/kg Met or equal volumes of Saline was gavaged daily as indicated. Met was used as a positive control; (b) Representative echocardiographic M-mode images of left ventricles from mice at day 8; (c) Echocardiographic measurement of LVEF (n = 6); (d) Echocardiographic measurement of LVFS (n = 6); (e) Quantitative analysis of LVPW;d (n = 6); (f) The mRNA levels of ANP in heart tissues (n = 6); (g) The mRNA levels of BNP in heart tissues (n = 6); Quantification of ANP and BNP were normalized to GAPDH. The data are shown as mean ± SEM (one-way ANOVA with Tukey’s post-hoc multiple comparison tests). ***, p < 0.001, ****, p < 0.0001 vs. Saline; #, p < 0.05, ##, p < 0.01, ###, p < 0.001, ####, p < 0.0001 vs. ISO. ISO, isoproterenol; Met, metoprolol; ZB, Zanubrutinib; LVEF, left ventricular ejection fraction; LVFS, left ventricular fractional shortening; LVPW;d, diastolic left ventricular posterior wall thickness.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.